scFv Antibody Discovery Service

Alpha Lifetech Inc. offers comprehensive scFv library construction services tailored to the diverse needs of researchers worldwide. We are committed to delivering reliable, high-quality solutions that address both established and emerging challenges in antibody research.

What Is scFv- Single Chain Variable Fragment Antibody?

A single-chain variable fragment (scFv) antibody comprises a variable light (VL) and variable heavy (VH) chain connected by a flexible peptide linker. As the smallest functional unit of an immunoglobulin molecule capable of antigen binding, scFv fragments are widely used in protein engineering to enhance antibody affinity and specificity. At Alpha Lifetech, scFv antibodies are constructed from hybridoma cells, immunized mouse spleen cells, and human B lymphocytes. Total RNA is extracted from these sources, reverse-transcribed into cDNA, and subsequently amplified via PCR for antibody gene library generation.

scFv Antibody Development-Phage Display Technology

Library diversity is defined by the number of independent clones. To generate large-scale scFv libraries, we employ a proprietary two-step strategy. In the first step, primary repertoires are prepared from PCR products encoding the VH, V_κ, and V_λ domains, yielding medium-sized libraries of 1–100 million clones. In the second step, VH (or VL) fragments are isolated by plasmid digestion, then cloned into an acceptor phagemid vector carrying the complementary VL (or VH) repertoire. This combinatorial approach expands library size dramatically, reaching 10¹⁰–10¹² clones.

Large-scale and high throughput Screening of scFv Antibody

Expression host selection is a critical determinant of scFv production efficiency, directly influencing process design, downstream processing, and overall cost. The optimal manufacturing route depends on the requirement for post-translational modifications, clinical development timelines, and economic considerations. Since no single expression system universally guarantees high-yield output across all antibody formats, we evaluate each project individually to identify the most suitable platform.